- Home
- NUVB vs MLAB Comparison
NUVB vs MLAB Comparison
Compare NUVB & MLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVB
- MLAB
- Stock Information
- Founded
- NUVB 2018
- MLAB 1982
- Country
- NUVB United States
- MLAB United States
- Employees
- NUVB N/A
- MLAB N/A
- Industry
- NUVB Biotechnology: Pharmaceutical Preparations
- MLAB Industrial Machinery/Components
- Sector
- NUVB Health Care
- MLAB Industrials
- Exchange
- NUVB Nasdaq
- MLAB Nasdaq
- Market Cap
- NUVB 679.9M
- MLAB 680.0M
- IPO Year
- NUVB N/A
- MLAB N/A
- Fundamental
- Price
- NUVB $1.97
- MLAB $112.01
- Analyst Decision
- NUVB Strong Buy
- MLAB Hold
- Analyst Count
- NUVB 5
- MLAB 2
- Target Price
- NUVB $8.00
- MLAB $140.00
- AVG Volume (30 Days)
- NUVB 3.3M
- MLAB 58.3K
- Earning Date
- NUVB 05-13-2025
- MLAB 05-30-2025
- Dividend Yield
- NUVB N/A
- MLAB 0.57%
- EPS Growth
- NUVB N/A
- MLAB N/A
- EPS
- NUVB N/A
- MLAB N/A
- Revenue
- NUVB $7,873,000.00
- MLAB $237,747,000.00
- Revenue This Year
- NUVB $75.73
- MLAB $13.48
- Revenue Next Year
- NUVB $440.21
- MLAB $4.74
- P/E Ratio
- NUVB N/A
- MLAB N/A
- Revenue Growth
- NUVB N/A
- MLAB 11.68
- 52 Week Low
- NUVB $1.54
- MLAB $83.68
- 52 Week High
- NUVB $3.97
- MLAB $155.12
- Technical
- Relative Strength Index (RSI)
- NUVB 52.62
- MLAB 42.12
- Support Level
- NUVB $1.82
- MLAB $109.95
- Resistance Level
- NUVB $2.08
- MLAB $117.85
- Average True Range (ATR)
- NUVB 0.18
- MLAB 8.18
- MACD
- NUVB 0.04
- MLAB 0.63
- Stochastic Oscillator
- NUVB 79.63
- MLAB 59.94
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).
About MLAB Mesa Laboratories Inc.
Mesa Laboratories Inc manufactures life sciences tools and critical quality control products. It operates in 4 divisions: Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. Clinical Genomics division develops, manufactures, and sells highly sensitive, low-cost, high-throughput genetic analysis tools and related consumables. The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. The Calibration Solutions division develops, manufactures, sells, and services quality control products.